Search

Displaying results 961 - 970 of 10000 in total
  1. Drug

    Bintrafusp alfa

    go.drugbank.com/drugs/DB15387
    Investigational

    Bintrafusp alfa is under investigation in clinical trial NCT03833661 (M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer

  2. Drug

    Glofitamab

    go.drugbank.com/drugs/DB16371
    ApprovedInvestigational

    [L45768] The most common type of non-Hodgkin lymphoma,[L45763] DLBCL is relatively sensitive to chemotherapy and generally responsive to first-line treatment regimens like CHOP ([cyclophosphamide], [doxorubicin … [L45768,A258433] In the context of relapsed or refractory DLBCL, glofitamab provides an alternative treatment option for patients having failed other systemic therapies or for whom targeted therapies -

  3. Drug

    Palivizumab

    go.drugbank.com/drugs/DB00110
    ApprovedInvestigational

    Palivizumab is expressed from a stable murine (mouse) myeloma cell line (NS0). … Humanized monoclonal antibody (IgG1k) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV).

  4. Drug

    Undecylenic acid

    go.drugbank.com/drugs/DB11117
    Approved

    It serves as an acid moiety for anabolic steroid boldenone. … Undecylenate, or undecylenic acid, is an unsaturated fatty acid with a terminal double bond that is derived from castor oil. Undecylenic acid is also found naturally in the human sweat.

    Mixtures: Desenex Medicated Spray-ON Powder, Desenex Medicated Spray-ON PowderProducts: CVS Pharmacy Maximum Strength Antifungal Liquid with Aloe and Vitamin E, Anti-Fungal Pen CVS
  5. Drug

    Favezelimab

    go.drugbank.com/drugs/DB16729
    Investigational

    Favezelimab is under investigation in clinical trial NCT04626479 (Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A

  6. Drug

    Eftrenonacog alfa

    go.drugbank.com/drugs/DB11608
    Approved

    It is comprised of a single molecule of human factor IX (FIX) covalently linked to the constant region (Fc) domain of human IgG1 via recombinant DNA technology in a human embryonic kidney cell line (HEK293H … It was first approved by the FDA in March 2014 and later approved by the EMA in May 2016.

  7. Drug

    Ramucirumab

    go.drugbank.com/drugs/DB05578
    ApprovedInvestigational

    In contrast to other agents directed against VEGFR-2, ramucirumab binds a specific epitope on the extracellular domain of VEGFR-2, thereby blocking all VEGF ligands from binding to it. … Ramucirumab is indicated for us in advanced gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel after prior fluoropyrimidine- or platinum-containing

  8. Drug

    Gastric intrinsic factor

    go.drugbank.com/drugs/DB09349
    Approved

    in the small intestine. … However, it is currently in the marketed (but unapproved) product Hematogen in combination with cyanocobalamin (synthetic Vitamin B12), ferrous fumarate, and ascorbic acid for the treatment of anemias

    Mixtures: EnLyte Extra-LN
  9. Drug

    Anise oil

    go.drugbank.com/drugs/DB15776
    Investigational

    Mixtures: FINIGAX PLUS CON ANIS - GOTAS, FINIGAX PLUS CON ANIS- TABLETAMASTICABLE
  10. Drug

    Streptococcus pneumoniae type 5 capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10323
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.

    Mixtures: SYNFLORIX 0,5 ML IM ENJ. ICIN SUS.ICEREN KUL.HAZIR ENJEKTOR, PNEUMOVAX 23 Injektionslösung in einer Fertigspritze